ELUCIDATING RESISTANCE MECHANISM TO PARP INHIBITORS FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES IN HIGH-GRADE SEROUS OVARIAN CANCER

被引：1
|
作者：
Kulbe, Hagen [1 ]
Kassuhn, Wanja [2 ,3 ,4 ,5 ]
Ringel, Frauke [2 ,3 ,4 ,5 ]
Welsch, Gabriele [2 ,3 ,4 ,5 ]
Treffkorn, Peggy [2 ,3 ,4 ,5 ]
Taube, Eliane [2 ,3 ,4 ,5 ]
Horst, David [2 ,3 ,4 ,5 ]
Sehouli, Jalid [2 ,3 ,4 ,5 ]
Braicu, Elena [2 ,3 ,4 ,5 ]
机构：
[1] Charite Univ Med Berlin, Dept Gynecol, Campus Virchow Clin, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Berlin Inst Hlth, Berlin, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
416
引用
收藏
页码：A79 / A79
页数：1
相关论文
共 50 条
  • [1] Elucidating resistance mechanism to PARP inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer.
    Kulbe, Hagen
    Kassuhn, Wanja Nikolai
    Ringel, Frauke
    Welsch, Gabriele
    Treffkorn, Peggy
    Taube, Eliane T.
    Horst, David
    Sehouli, Jalid
    Braicu, Ioana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [3] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [4] PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
    Dickson, Kristie-Ann
    Xie, Tao
    Evenhuis, Christian
    Ma, Yue
    Marsh, Deborah J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [5] Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer (HGSOC)
    Durmaz, Irem
    Hedenfalk, Ingrid
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
    Jia, Yaxun
    Wang, Min
    Sang, Xiaolin
    Liu, Pixu
    Gao, Jingchun
    Jiang, Kui
    Cheng, Hailing
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [7] Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
    Karime Kalil Machado
    Stéphanie L. Gaillard
    Current Obstetrics and Gynecology Reports, 2017, 6 (3) : 207 - 218
  • [8] Identification of novel therapeutic targets to overcome chemoresistance in high-grade serous ovarian cancer
    Christie, E.
    Huang, C.
    Zhang, V.
    Cowley, K.
    Simpson, K.
    Wang, G.
    Cao, P.
    Wiedemeyer, W.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S113 - S113
  • [9] Static and microfluidic platforms for novel therapeutic testing in high-grade serous ovarian cancer
    Cavarzerani, Enrico
    Saorin, Gloria
    Mauceri, Matteo
    Caligiuri, Isabella
    Bartoletti, Michele
    Canzonieri, Vincenzo
    Rizzolio, Flavio
    CANCER RESEARCH, 2024, 84 (07)
  • [10] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2016, 22
12345